{
    "pmid": "41457070",
    "title": "HTRF-based identification of small molecules targeting SARS-CoV-2 E protein interaction with ZO-1 PDZ2.",
    "abstract": "The SARS-CoV-2 E protein through its C-terminal PDZ-binding motif (PBM) interacts with several host PDZ-containing proteins, including Zonula occludens-1 (ZO-1) protein via its PDZ2 domain, thereby contributing to viral pathogenesis. Targeting this interaction represents a potential therapeutic strategy. In this study, we determined the X-ray structure of the E PBM peptide in complex with the ZO-1 PDZ2 domain at 1.7 Ã… resolution. The structure revealed a domain-swapped dimer conformation of ZO-1 PDZ2, with the E PBM peptide conventionally bound within the PDZ domain's canonical binding groove, exhibiting key interactions characteristic of type II PBM/PDZ interactions. To identify potential inhibitors of the E PBM/ZO-1 PDZ2 interaction, we performed a Homogeneous Time-Resolved Fluorescence (HTRF) screening using a protein-protein interaction-focused library of 1000 compounds. This led to the identification of 36 hits that disrupted this interaction. Subsequent cytotoxicity and dose-response assays narrowed the selection to 14 promising compounds. Docking simulations showed that some compounds bind within or near the PBM-binding pocket, supporting a competitive mechanism of interaction inhibition, while others bind at a central interface between the two PDZ monomers, suggesting an inhibition of dimerization, which in turn prevents PBM binding. Thus, the E PBM/ZO-1 PDZ2 interaction can be inhibited through both direct and indirect mechanisms. Finally, antiviral assays using a NanoLuciferase-expressing recombinant SARS-CoV-2 demonstrated that one compound, C19, significantly reduced viral replication, highlighting its potential as a candidate for further therapeutic development.",
    "disease": "covid-19",
    "clean_text": "htrf based identification of small molecules targeting sars cov e protein interaction with zo pdz the sars cov e protein through its c terminal pdz binding motif pbm interacts with several host pdz containing proteins including zonula occludens zo protein via its pdz domain thereby contributing to viral pathogenesis targeting this interaction represents a potential therapeutic strategy in this study we determined the x ray structure of the e pbm peptide in complex with the zo pdz domain at resolution the structure revealed a domain swapped dimer conformation of zo pdz with the e pbm peptide conventionally bound within the pdz domain s canonical binding groove exhibiting key interactions characteristic of type ii pbm pdz interactions to identify potential inhibitors of the e pbm zo pdz interaction we performed a homogeneous time resolved fluorescence htrf screening using a protein protein interaction focused library of compounds this led to the identification of hits that disrupted this interaction subsequent cytotoxicity and dose response assays narrowed the selection to promising compounds docking simulations showed that some compounds bind within or near the pbm binding pocket supporting a competitive mechanism of interaction inhibition while others bind at a central interface between the two pdz monomers suggesting an inhibition of dimerization which in turn prevents pbm binding thus the e pbm zo pdz interaction can be inhibited through both direct and indirect mechanisms finally antiviral assays using a nanoluciferase expressing recombinant sars cov demonstrated that one compound c significantly reduced viral replication highlighting its potential as a candidate for further therapeutic development"
}